ANNEXON, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
ANNEXON, INC. (ANNX) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of $37.22 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Change in Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-12
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was $13.16M, a 72.38% decline year-over-year.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was $47.62M.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$73.16M, a 1882.14% decline year-over-year.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was $4.11M, a 89.19% decline year-over-year.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $112.55M.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$175.60M, a 306.38% decline from fiscal 2023.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was $85.08M, a 30.82% increase from fiscal 2022.
- ANNEXON, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $65.04M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month as first filed | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $37.22M 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $13.16M 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | $112.55M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $89.92M 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $82.79M 10-Q · filed 2026-08-12 | ||||
| 2025-03-31 | $47.62M 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | -$175.60M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | -$145.56M 10-Q · filed 2025-11-10 | ||||
| 2024-06-30 | -$67.80M 10-Q · filed 2025-08-14 | ||||
| 2024-03-31 | -$73.16M 10-Q · filed 2025-05-12 | ||||
| 2023-12-31 | $85.08M 10-K · filed 2025-03-03 | ||||
| 2023-09-30 | -$6.85M 10-Q · filed 2024-11-14 | ||||
| 2023-06-30 | -$26.40M 10-Q · filed 2024-08-12 | ||||
| 2023-03-31 | $4.11M 10-Q · filed 2024-05-13 | ||||
| 2022-12-31 | $65.04M 10-K · filed 2024-03-26 | ||||
| 2022-09-30 | $135.69M 10-Q · filed 2023-11-13 | ||||
| 2022-06-30 | $29.64M 10-Q · filed 2023-08-07 | ||||
| 2022-03-31 | $37.98M 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | -$192.55M 10-K · filed 2023-03-06 | ||||
| 2021-09-30 | -$198.88M 10-Q · filed 2022-11-03 | ||||
| 2021-06-30 | -$167.81M 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | -$60.75M 10-Q · filed 2022-05-09 | -$60.73M 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | $224.63M 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | $326.75M 10-Q · filed 2021-11-09 | ||||
| 2020-06-30 | $80.83M 10-Q · filed 2021-08-16 | ||||
| 2020-03-31 | -$10.57M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |